[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359854-105":59,"doc-detail-359854-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","clinical-data-analysis-identifies-prognostic-long-non-coding-rna-signatures-in-lung-adenocarcinoma","Clinical Data Analysis Identifies Prognostic Long Non-coding RNA Signatures in Lung Adenocarcinoma","","Integrative clinical data analysis focuses on lung adenocarcinoma (LUAD), a common non-small cell lung cancer subtype with poor outcomes driven by molecular heterogeneity and limited prognostic biomarkers. Pre-processed lncRNA expression profiles from 488 LUAD tumors and 58 normal tissues were analyzed using Welch’s t-tests with false discovery rate correction, with survival assessed by Kaplan–Meier and monotonic trends by Spearman correlation across tumor stage, nodal status, and size. The study highlights 68 consistently upregulated lncRNAs and pinpoints FAM83A-AS1, CYTOR, and MIR4435-2HG as robust poor-prognosis candidates.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-data-analysis-identifies-prognostic-long-non-coding-rna-signatures-in-lung-adenocarcinoma/359854/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-data-analysis-identifies-prognostic-long-non-coding-rna-signatures-in-lung-adenocarcinoma/359854.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of the study on LUAD?","Question",{"text":113,"@type":114},"To identify long non-coding RNAs (lncRNAs) that robustly associate with LUAD progression and prognosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which datasets and analysis approaches were used to derive prognostic candidates?",{"text":118,"@type":114},"Pre-processed lncRNA expression data from TCGA via TANRIC were filtered, followed by Welch’s t-tests with false discovery rate correction, Kaplan–Meier survival analysis, and Spearman trend analyses across stage, lymph-node status, and tumor size.",{"name":120,"@type":111,"acceptedAnswer":121},"Which lncRNAs emerged as the most prominent poor-prognosis candidates?",{"text":122,"@type":114},"FAM83A-AS1, CYTOR, and MIR4435-2HG showed consistent tumor-associated overexpression and adverse survival associations, with significant monotonic trends across increasing lymph-node involvement and primary tumor size.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359854,1790534582,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","doi: 10.21873/cgp.20588  \nClinical Data Analysis Identifies Prognostic Long  \nNon-coding RNA Signatures in Lung Adenocarcinoma  \nMADHUR SHARMA1, NIDHICHOURASIA2, PRIYANKA PRIYANKA3, MOHIT GARG2, SARANGADHAR NAYAK2,  \nSANAN SHOWKAT SHAH4, PAWAN KUMAR DHAR5, DEBI PRASAD SARKAR1,6, ALO NAG1 and SANDEEP SAXENA2 1 Department of Biochemistry, University of Delhi South Campus, New Delhi, India;  \n2School of Biotechnology, Jawaharlal Nehru University, New Delhi, India;  \n3Cellular and Molecular Medicine, Department of Medicine, University of California San Diego, San Diego, CA, U.S.A.; 4 Department of Biotechnology, School of Life Sciences, Central University of Kashmir, Ganderbal, India;  \n5CVJ Centre for Synthetic Biology & Bio-Manufacturing, TBI Student Amenity Centre, Cochin University of Science and Technology, Kochi, India;  \n6 Department of Biological Sciences and Engineering, Indian Institute of Technology, Gandhinagar, India  \nAbstract  \nBackground/Aim: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and remains associated with poor clinical outcomes due to pronounced molecular heterogeneity and limited prognostic biomarkers. Long non-coding RNAs (lncRNAs) have emerged as important regulators of cancer biology, yet their systematic association with disease progression and survival in LUAD remains incompletely defined. This study aimed to identify lncRNAs that robustly associate with LUAD progression and prognosis.  \nMaterials and Methods: Pre-processed lncRNA expression data for 488 LUAD tumorsand 58 normal lung tissues were obtained from The Cancer Genome Atlas (TCGA) via the TANRIC platform. Following expression filtering, stage-wise differential expression analysis was performed using Welch’st-test with false discovery rate correction. Kaplan–Meier survival analysis was used to evaluate prognostic relevance. Rank-based trend analyses using Spearman correlation were conducted to assess monotonic expression changes across tumor stage, lymph-node status, and tumor size. Results: We identified 68 lncRNAs consistently upregulated across all LUAD stages relative to normal lung tissue. Survival analysis revealed that higher expression of several lncRNAs was associated with poorer overall survival. Among these, FAM83A-AS1, CYTOR, and MIR4435-2HG emerged as prominent candidates, exhibiting consistent tumor-associated overexpression and adverse survival association. Importantly, these three lncRNAs also demonstrated significant monotonic trends across increasing lymph-node involvement and primary tumor size, indicating a close association with tumor burden and disease aggressiveness.  \ncontinued  \n✉ Sandeep Saxena, School of Biotechnology, JNU, New Delhi 110067, India. Tel: +91 1126704089, e-mail: sandeepsaxena@  \n[mail.jnu.ac.in](mail.jnu.ac.in)  \nReceived October 16, 2025 | Revised February 19, 2026 | Accepted March 2, 2026  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nConclusion: This integrative analysis identifies FAM83A-AS1, CYTOR, and MIR4435-2HG as robust poor-prognosisassociated lncRNAs in LUAD. Their coordinated behavior across expression, survival, nodal status, and tumor size highlights their potential utility as prognostic biomarkers and provides a framework for lncRNA-based risk stratification in lung adenocarcinoma.  \nKeywords: Long non-coding RNA, long ncRNA, LncRNA, prognostic biomarker, LUAD, cancer transcriptomics, functional enrichment analysis.  \nIntroduction  \nLung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer (NSCLC), accounting for approximately 40% of all lung cancer cases worldwide (1, 2) . Despite advancements in diagnostic and therapeutic strategies, LUAD rema","cbCaif8tpDpxZZRM","https://ap.wps.com/l/cbCaif8tpDpxZZRM","pdf",5541868,16,"English","# Abstract\n## Background/Aim\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n## Disease burden and current limitations\n## Role of long non-coding RNAs in cancer","[{\"question\":\"What is the main objective of the study on LUAD?\",\"answer\":\"To identify long non-coding RNAs (lncRNAs) that robustly associate with LUAD progression and prognosis.\"},{\"question\":\"Which datasets and analysis approaches were used to derive prognostic candidates?\",\"answer\":\"Pre-processed lncRNA expression data from TCGA via TANRIC were filtered, followed by Welch’s t-tests with false discovery rate correction, Kaplan–Meier survival analysis, and Spearman trend analyses across stage, lymph-node status, and tumor size.\"},{\"question\":\"Which lncRNAs emerged as the most prominent poor-prognosis candidates?\",\"answer\":\"FAM83A-AS1, CYTOR, and MIR4435-2HG showed consistent tumor-associated overexpression and adverse survival associations, with significant monotonic trends across increasing lymph-node involvement and primary tumor size.\"}]","Clinical Data Analysis Identifies Prognostic Long Non-coding RNA Signatures in Lung Adenocarcinoma | PDF",1790138018,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d23d12e08f60db606c622553bd0f3d8.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/755f0d477cf1b11a414a164d30d048d1.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d0416f45a6c0d01bc80bd0c11fe6567.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ded44dd4d92f9db6c7ae5455d502bc71.webp",980,1306]